In addition, treatment with PG545 was associated with reduced phosphorylation levels of Erk (Figure 6, second panel), a most important determinant in non-small cell lung cancer [35], and in agreement with a connection between heparanase and Erk phosphorylation reported in other settings [26, 36–41]. Here, HPSE is linked to non-small cell lung carcinoma.